European Journal of Medicinal Chemistry p. 562 - 575 (2019)
Update date:2022-08-30
Topics:
Yan, Zhiqiang
Chong, Shuyi
Lin, Huiyun
Yang, Qian
Wang, Xin
Zhang, Weidong
Zhang, Xiaokun
Zeng, Zhiping
Su, Ying
Nuclear receptor RXRα plays an important role in many biological and pathological processes. The nongenomic action of RXRα is implicated in many cancers. K-8008, a non-canonical RXRα ligand derived from sulindac, inhibits the TNFα-activated PI3K/AKT pathway by mediating the interaction between a truncated form of RXRα (tRXRα) and the p85α regulatory subunit of PI3K and exerts potent anticancer activity in animal model. Herein we report our studies of a novel series of K-8008 analogs as potential anticancer agents targeting RXRα. Two compounds 8b and 18a were identified to have slightly stronger binding to RXRα and improved apoptotic activities in breast cancer cells.
View MoreContact:+86 21 5017 5386
Address:No 999,Jiangyue Rd, Minhang Dist ,201114,Shanghai ,China
Tianjin Puck Rice Chemicals Co., Ltd.
Contact:022-58054572
Address:Weidi Road
Guangxi Nanning Guangtai Agriculture Chemical Co.,Ltd
Contact:+86-771-2311266
Address:Room703,Building12, Software Park Phase II,NO.68,Keyuan Road,Nanning City,Guangxi,China
Beijing Cooperate Pharmaceutical Co.,Ltd
Contact:86-01060279497
Address:No.507,Building 4,Tianhua Street, Biomedicine industrial Base
Contact:852-27701081
Address:Room 2509, New Tech Plaza, 34 Tai Yau St., San Po Kong, HK
Doi:10.1007/BF00497211
(1990)Doi:10.1021/acs.orglett.6b02301
(2016)Doi:10.1016/j.tetlet.2007.07.018
(2007)Doi:10.1021/jp9609500
(1997)Doi:10.1021/acscatal.1c02140
(2021)Doi:10.1021/jo01273a080
(1968)